title: Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
abstract: Bone marrow BCR-ABL transcript levels were monitored serially by real-time quantitative PCR in 46 imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response (CCyR) for a median of 42 months (range: 9-53). Of 41 patients in continuous CCyR, 32 and nine could achieve a >/=3-log (MMoR group) or 2- to 3-log reduction (non-MMoR group), respectively. The MMoR group had a significantly lower recurrence rate of Ph+ metaphase than the non-MMoR group (6/32 vs. 7/9, P = 0.002), which was not significantly different between patients first achieving CCyR within or after 12 months of imatinib treatment (7/27 vs. 6/14, P = 0.086). Five patients suffered cytogenetic or hematological relapse. For all 46 patients, a >2-log reduction but not time when CCyR was first achieved was related to a lower relapse rate (1/42 vs. 4/4, P < 0.001). We concluded that the depth of BCR-ABL reduction after CCyR is more critical than when CCyR is first achieved. The kinetic pattern of BCR-ABL transcript is a good predictor of disease stability.
authors.affiliation: Institute of Hematology, People's Hospital, Peking University, Peking, China.
authors.forename: Y Z
authors.initials: YZ
authors.lastname: Qin
authors.forename: Y R
authors.initials: YR
authors.lastname: Liu
authors.forename: H H
authors.initials: HH
authors.lastname: Zhu
authors.forename: J L
authors.initials: JL
authors.lastname: Li
authors.forename: G R
authors.initials: GR
authors.lastname: Ruan
authors.forename: Y
authors.initials: Y
authors.lastname: Zhang
authors.forename: Q
authors.initials: Q
authors.lastname: Jiang
authors.forename: H
authors.initials: H
authors.lastname: Jiang
authors.forename: L D
authors.initials: LD
authors.lastname: Li
authors.forename: Y
authors.initials: Y
authors.lastname: Chang
authors.forename: X J
authors.initials: XJ
authors.lastname: Huang
authors.forename: S S
authors.initials: SS
authors.lastname: Chen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001549:Benzamides; D020732:Cytogenetic Analysis; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000175:diagnosis / Q000235:genetics; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000032:analysis / Q000378:metabolism*; D012074:Remission Induction; D014158:Transcription, Genetic
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D012333:RNA, Messenger; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl